Xtant Medical Holdings, Inc.
DB:XMS Stock Report
Xtant Medical Holdings Balance Sheet Health
Financial Health criteria checks 5/6 Xtant Medical Holdings has a total shareholder equity of $45.0M and total debt of $33.7M, which brings its debt-to-equity ratio to 74.8%. Its total assets and total liabilities are $95.6M and $50.6M respectively.
Key information
74.8%
Debt to equity ratio
Interest coverage ratio n/a Cash US$5.38m Equity US$45.01m Total liabilities US$50.57m Total assets US$95.58m
Recent financial health updates
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07
Show all updates
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18
New major risk - Share price stability Sep 05 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2023) Aug 09
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 Aug 09 Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024 Jun 13
New minor risk - Profitability Jun 07
New minor risk - Financial position May 17
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024 May 17
Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds May 01
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds Apr 30
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 03
Full year 2023 earnings released: EPS: US$0.006 (vs US$0.09 loss in FY 2022) Apr 02
Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 22
Investor sentiment improves as stock rises 23% Feb 29
Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.025 loss in 3Q 2022) Nov 10
Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2022) Aug 02
Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26 Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding Jul 04
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Jun 21
Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors May 19
First quarter 2023 earnings released: US$0.019 loss per share (vs US$0.025 loss in 1Q 2022) May 07
Xtant Medical Holdings, Inc. Announces Executive Changes May 06
Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021) Mar 09
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023 Feb 02
Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023 Jan 10
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021) Nov 04
Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022 Sep 01 Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding
Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021) Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings released: US$0.025 loss per share (vs US$0 in 1Q 2021) May 06
Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 09
Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020) Aug 09
Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding Feb 26
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019) Feb 25
Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding Feb 24
Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €1.49 Feb 11
New 90-day high: €1.20 Jan 24
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue misses expectations Oct 30
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07 Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding
New 90-day low: €0.65 Sep 28
New 90-day low - €0.66 Sep 11
New 90-day low - €0.76 Aug 21
First half earnings released Aug 04
Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index Jul 05
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index Jul 02
Financial Position Analysis
Short Term Liabilities: XMS's short term assets ($69.0M) exceed its short term liabilities ($28.3M).
Long Term Liabilities: XMS's short term assets ($69.0M) exceed its long term liabilities ($22.3M).
Debt to Equity History and Analysis
Debt Level: XMS's net debt to equity ratio (62.9%) is considered high .
Reducing Debt: XMS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XMS has sufficient cash runway for 4 months based on last reported free cash flow , but has since raised additional capital.
Forecast Cash Runway: XMS has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 52.4% each year.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}